Search
for
Sort by
Research 211–240 of 1000+
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Baricitinib for the Treatment of Alopecia Areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Exploring novel management options for alopecia areata
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Finasteride Treatment of Hair Loss in Women
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- 4. Bullous/Mucous Membrane
- 1. Medical Practice; Therapy; Adverse Reactions
- 13. Wound Healing & Hair
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Teledermatology Service During the COVID-19 Pandemic in China: A Mobile Application-Based Retrospective Study
- TACRINE
- Erosive pustular dermatosis of the scalp successfully treated with oral prednisone and topical tacrolimus